The Trump administration has enacted a comprehensive policy prohibiting federal Medicaid and CHIP funds from supporting gender-affirming medical treatments for transgender youth. This regulatory decision represents a significant shift in healthcare policy, affecting vulnerable populations who rely on government insurance programs. The rule restricts access to treatments previously covered under these programs, marking a contentious development in the ongoing debate over transgender healthcare rights and government funding priorities.

Summary auto-generated by AI from the original publisher's content. Editorial standards.